Conestoga Capital Advisors , an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here . In 2026, Small Caps initially outperformed but faced challenges in the third quarter, marked by the Russell 2000 Growth Index's -9.4% decline versus the S&P 500's +2.3% rise. Factors such as rising Treasury yields and higher oil prices due to geopolitical tensions, especially in Iran, played a role. The Federal Reserve's policy shifts influenced market sentiment, leading to a selloff in AI and semiconductor stocks, although a stable Fed outlook provided a temporary recovery. The Conestoga Small Cap Composite fell -11.22% in the quarter, underperforming the Russell 2000 Growth Index's -9.39% return, impacted by exposure to struggling sectors like Industrials and Consumer Discretionary, while Health Care and Technology showed resilience. The firm remains committed to owning high-quality companies with strong competitive moats and resilient growth, driving long-term value creation. Also, check the Fund's top five holdings to see its best picks for 2026.
In its Q3 2026 investor letter, Conestoga Capital Advisors highlighted Stevanato Group S.p.A. (NYSE: STVN ). Stevanato Group S.p.A. (NYSE:STVN) is an Italian company that designs and distributes products and processes that offer integrated solutions for the biopharma and healthcare industries. Stevanato Group S.p.A. (NYSE:STVN) closed at $19.64 on October 27, 2026, with a market capitalization of $5.36 billion. Stevanato Group S.p.A. (NYSE:STVN) stock shows a 2.39% YTD decline, trading within a 52-week range of $12.89 to $27.00.
Conestoga Capital Advisors stated the following regarding Stevanato Group S.p.A. (NYSE:STVN) in its Q3 2026 investor letter:
"Stevanato Group S.p.A.(NYSE:STVN) provides drug containment and delivery solutions primarily to pharmaceutical and biotechnology companies. In 2Q26, the company reported 8% revenue growth as well as expanded EBITDA margins (Earnings before interest, taxes, depreciation, and amortization) margins. Investor sentiment improved as the company's shift toward higher-value products continued to gain traction, particularly within biologics and GLP-1 therapies. High-value solutions grew 16% in 2Q, and an improving product mix contributed to margin expansion. STVN also made progress ramping its manufacturing investments in the U.S. and Italy, which are intended to provide additional capacity for growing demand for premium injectable drug delivery solutions."
Stevanato Group S.p.A. (NYSE: STVN) is not on our list of the 40 Most Popular Stocks Among Hedge Funds . As per our database, 18 hedge fund portfolios held Stevanato Group S.p.A. (NYSE: STVN) at the end of the second quarter which was 21 in the previous quarter. While we acknowledge the risk and potential of Stevanato Group S.p.A. (NYSE:STVN) as an investment, we believe certain AI infrastructure stocks offer far stronger long-term potential at a much more attractive entry point. If you are looking for an AI stock more promising than STVN that operates as a critical AI tollboothand stands as the most important company in the world, check out our report about this must-own AI stock .
In another article we covered Stevanato Group S.p.A. (NYSE:STVN) and outlined Riverwater Partners' investment thesis for initiating a position last quarter. In addition, please check out our hedge fund investor letters Q3 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years .
This article is originally published at Insider Monkey .
